HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)
Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)
Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
This observational or N/A phase trial investigates Hepatocellular Carcinoma and is currently ongoing. Fifth Affiliated Hospital, Sun Yat-Sen University leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Oct 2018 — Oct 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Third Affiliated Hospital, Sun Yat-Sen University
For direct contact, visit the study record on ClinicalTrials.gov .